Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

NanoRepro: supervisory board member Stiller buys 2,688 shares at €1.86

Dr. Olaf Stiller, a member of NanoRepro’s supervisory board, reported on 18 August 2026 that he purchased 2,688 shares on 17 August 2026 at €1.86 each. Previously, on 31 July 2026 Stiller had bought 5,262 shares at €1.90 each. The stock showed little movement in trading; market capitalization €26.28 million, free float 13,903,603 shares. » Altro su finanzen.net
NanoRepro board member Jüngst acquires 5,435 shares

On 29 May 2026 Lisa Jüngst bought 5,435 NanoRepro shares at €1.84 each; the transaction was reported on 1 June 2026. The stock showed only slight price movement in FSE trading and closed around €1.73–1.74. Previously, additional purchases by Jüngst of 6,984 shares at €1.84 each had already been recorded. » Altro su finanzen.net
NanoRepro: supervisory board member Stiller makes share purchases (28.05.2026)

On 28.05.2026 NanoRepro reported a managers' transaction: supervisory board member Stiller, Dr. Olaf, initially bought 30 shares at €1.73 and earlier purchased 10,000 shares at €1.75 each. The transactions were published on 29.05.2026. The stock then traded stable in FSE trading around €1.71–€1.78. Market capitalization is approximately €24.75 million. » Altro su finanzen.net

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2023, NanoRepro ha già distribuito 0,15€ di dividendi. L'ultimo pagamento è avvenuto a giugno 2023.

Dati finanziari dell'azienda

Nell'ultimo trimestre, NanoRepro ha registrato ricavi pari a 1,91M€ e un utile netto di −1,14M€

(EUR)	dic 2025	YoY
Ricavi	+1,91M	-
Utile lordo	+224,20k	-
Utile netto	−1,14M	-
EBITDA	−1,28M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+23,21M€
Numero di azioni	12,61M
Massimo/minimo a 52 settimane	+2,40€ - +1,31€
Dividendi	No
Beta	0,52
Rapporto P/E	−11,68
Rapporto PEG	+3,27
Rapporto P/B	+0,64
Rapporto P/S	+5,35

Profilo aziendale

Die NanoRepro AG entwickelt, produziert und vertreibt in Deutschland und international diagnostische Schnelltests und Nahrungsergänzungsmittel für den privaten und professionellen Gebrauch. Das Unternehmen bietet Produkte in den Bereichen Familienplanung und Krankheitserkennung sowie Nahrungsmittelunverträglichkeiten, Allergien und Infektionskrankheiten an. Das Unternehmen bietet diagnostische Schnelltests an, darunter Produkte für die Bereiche Allergie, Familienplanung und Gesundheitsvorsorge; Point-of-Care-Tests für Krankenhäuser und Arztpraxen zum Nachweis von HIV, humanem kardialem Troponin I, D-Dimer, Streptokokken-Antigen, Influenza-Typ-A- und -B-Antigenen und Mikroalbumin; immunchromatographische Lateral-Flow-Tests für den diagnostischen Nachweis von Biomarkern sowie einen SARS-CoV-2-Antikörper-Schnelltest und einen Corona-Antigen-Schnelltest. Es bietet auch Nahrungsergänzungsmittel für Männer und Frauen über Online-Shops sowie über Apotheken an. Der Hauptsitz des Unternehmens befindet sich in Marburg, Deutschland.

Nome	NanoRepro
CEO	Lisa Jungst
Sede centrale	Marburg, he Germania
Sito web	nano.ag
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	22/10/2009
Dipendenti	22